ISM-001

ISM-001, our designated development candidate, will now complete a programme of pre-clinical activities, including safety/ toxicology studies, with our partner Pfizer Ignite.

The process development, formulation, scale-up and manufacture of the antibody for pre-clinical, and potentially clinical trials, has commenced under our Agreement with Catalent Inc.